PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

Shyamala C. Navada, MD^{* 1}, Guillermo Garcia-Manero, MD², Ehab Atallah, MD³, M. Nabeel Rajeh, MD⁴, Jamile M. Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Erin P. Demakos, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Shaker R. Dakhil, MD⁸, David E. Young, MD⁹, Rosalie Odchimar-Reissig, RN¹, Shaker R. Dakhil, MD⁸, ND⁸, Yesid Alvarado Valero, MD², Maro N. Ohanian, DO², Naveen Pemmaraju, MD², Rosmy B. John, MSN², Patrick S. Zbyszewski, MBA¹⁰, Michael E. Petrone, MD, MPH¹⁰, Richard C. Woodman, MD¹⁰, Steven M. Fruchtman, MD¹⁰, Lewis R. Silverman, MD¹

¹Mount Sinai Medical Center, New York, New, York; ²University of Texas MD Anderson Cancer Center, Houston, Texas; ³Froedtert Hospital & the Medical Center, Chicago, Illinois; ⁶Roswell Park Cancer Institute, Buffalo, New York; ⁴Saint Louis University, St. Louis, Missouri; ⁵Rush University, St. Louis, Missouri; ⁴Saint Louis University, St. Louis, Missouri; ⁵Rush University, St. Louis, Missouri; ⁴Saint Louis University, St. Louis, Missouri; ⁵Rush University, St. Louis, Missouri; ⁵Rush University, St. Louis, Missouri; ⁴Saint Louis University, St. Louis, Missouri; ⁵Rush University, S ⁷City of Hope, Duarte, California; ⁸Cancer Center of Kansas, Wichita, Kansas; ⁹Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California; ¹⁰Onconova Therapeutics, Inc., Newtown, Pennsylvania; United States.

ABSTRACT

Background: Azacitidine based combination trials have not demonstrated improved response or outcome over single agent azacitidine.^{1,2} Results of a Phase I/II study in MDS patients demonstrated oral rigosertib and standard-dose azacitidine to be well-tolerated with efficacy in HMA-naive and HMA-failure patients: at 560mg qAM/280mg qPM rigosertib dosing, overall response rate (ORR) was 77%; 88% for HMA-naive group, 60% for HMA-failure group. An increase in genitourinary (GU) adverse events was noted with the combination. Rigosertib at higher doses (1120 mg/day) yielded maximum ORR in lower-risk MDS and was thus investigated in additional cohorts.³ Risk-mitigation strategies were employed to reduce GU AEs.⁴

Methods: Oral rigosertib was administered twice daily on Day 1-21 of a 28-day cycle (840mg or 1120mg total); parenteral (SC or IV) azacitidine 75mg/m2/day was given for 7 days starting on Day 8 in patients with MDS including both HMA naive and HMA failures. A CBC was performed weekly and a bone marrow aspirate and/or biopsy were performed at baseline, D29, and then every 8 weeks thereafter. Response was determined by IWG criteria for MDS.⁶

Results: Of those patients receiving ≥840mg rigosertib, 55 were evaluable for response. 26 were treated with 840mg rigosertib and 29 were treated with 1120mg.

HMA NAIVE \geq 840MG/DAY

Evaluable for response	29*
Overall response per IWG 2006	26 (90%)
CR+PR	10 (34%)
Complete remission (CR)	10 (34%)
Partial remission (PR)	0
Marrow CR + Hematologic Improvement	5 (17%)
Hematologic Improvement alone	3 (10%)
Marrow CR alone	8 (28%)
Stable disease	3 (10%)
Progression	0
	12.2
Median duration of response (months)	(range, 0.1-24.2+)
	7.8
Median duration of treatment (months)	(range, 0.7-25.1+)
Median time to initial/best response (cycles) * Includ HMA FAILURE ≥ 840MG/DAY EFFICACY	es 2 patients treated with non-HMA, chemotherapy
<pre>* Includ # Includ # Includ EFFICACY</pre>	
<pre># Includ # Includ</pre> # Includ	es 2 patients treated with non-HMA, chemotherapy
* Includ HMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response	es 2 patients treated with non-HMA, chemotherapy
* Includ * Includ EFFICACY Evaluable for response Overall response per IWG 2006	es 2 patients treated with non-HMA, chemotherapy 26* 14 (54%)
<pre>* Includ #IMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR</pre>	26* 14 (54%) 2 (8%)
<pre>* Includ #IMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR)</pre>	26* 14 (54%) 2 (8%) 1 (4%)
<pre>*Includ #IMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR) Partial remission (PR)</pre>	26* 26* 14 (54%) 2 (8%) 1 (4%) 1 (4%)
<pre>* Includ HMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR) Partial remission (PR) Marrow CR + Hematologic Improvement</pre>	26* 26* 14 (54%) 2 (8%) 1 (4%) 1 (4%) 1 (4%) 5 (19%)
<pre>* Includ HMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR) Partial remission (PR) Marrow CR + Hematologic Improvement Hematologic Improvement alone</pre>	26* 26* 14 (54%) 2 (8%) 1 (4%) 1 (4%) 1 (4%) 5 (19%) 2 (8%)
<pre>* Includ HMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR) Partial remission (PR) Marrow CR + Hematologic Improvement Hematologic Improvement alone Marrow CR alone</pre>	26* 14 (54%) 2 (8%) 1 (4%) 1 (4%) 5 (19%) 5 (19%)
* Includ HMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR) Partial remission (PR) Marrow CR + Hematologic Improvement Hematologic Improvement alone Marrow CR alone Stable disease Progression	es 2 patients treated with non-HMA, chemotherapy 26* 14 (54%) 2 (8%) 1 (4%) 1 (4%) 1 (4%) 5 (19%) 2 (8%) 5 (19%) 7 (27%)
* Includ HMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR) Partial remission (PR) Marrow CR + Hematologic Improvement Hematologic Improvement alone Marrow CR alone Stable disease Progression	es 2 patients treated with non-HMA, chemotherapy 26* 14 (54%) 2 (8%) 1 (4%) 1 (4%) 5 (19%) 2 (8%) 5 (19%) 7 (27%) 5 (19%)
* Includ HMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR) Partial remission (PR) Marrow CR + Hematologic Improvement Hematologic Improvement alone Marrow CR alone Stable disease Progression Median duration of response (months)	es 2 patients treated with non-HMA, chemotherapy 26* 14 (54%) 2 (8%) 1 (4%) 1 (4%) 5 (19%) 2 (8%) 5 (19%) 7 (27%) 5 (19%) 10.8
* Includ HMA FAILURE ≥ 840MG/DAY EFFICACY Evaluable for response Overall response per IWG 2006 CR+PR Complete remission (CR) Partial remission (PR) Marrow CR + Hematologic Improvement Hematologic Improvement alone Marrow CR alone Stable disease Progression	26* 26* 14 (54%) 2 (8%) 1 (4%) 1 (4%) 1 (4%) 5 (19%) 2 (8%) 5 (19%) 7 (27%) 5 (19%) 10.8 (range, 0.1-11.8+)

REASONS FOR DISCONTINUATION

Reason for discontinuation		N=68*
	HMA Naive	HMA Failure
Progressive Disease	7	12
Toxicity / Adverse Event	8	5
Investigator Decision	5	4
Patient Request	7	2
Bone Marrow Transplant	5	3
No hematological response	3	3
Death	0	2
Disteasell refrapse	1	1

SAFETY OPTIMIZATION STRATEGIES

COMPARISON OF RIGOSERTIB DOSING GROUPS

Safety Optimization Stra	itegies		
2nd rigosertib dose	Oral hydration of at	Bladder	Urine pH 2 hours
must be administered	least two liters of	emptying prior	after AM dose.
at 3 PM (±1 hour) to	fluid daily	to bedtime	Suggested sodium
avoid a nocturnal			bicarbonate
bladder dwell time			administration if
			urine pH < 7.5
			Safety
			Optimization
			Strategies Applied
		Rigosertib 840mg	Rigosertib 1120mg
		42	43
Patients with hematuria		19 (45%)	17 (40%)
Patients with grade 1 or	2 hematuria only	14 (33%)	15 (35%)
Patients with grade 3 he	ematuria	5 (12%)	2 (5%)
Patients with dysuria		18 (43%)	13 (30%)
Patients with grade 1 or	2 dysuria only	13 (31%)	10 (23%)
•			
Patients with grade 3 dy No GR 4 reported	Suid	5 (12%)	3 (7%)

Median duration of response was 12.2 months (range, 0.1-24.2+) and 10.8 months (range, 0.1-11.8+) for HMA naive and HMA-failure pts, respectively. Median number of cycles to initial/best response was 1/4 and 2/5, respectively.

Responses per IWG 2006 occurred in all IPSS-R subgroups. In low/intermediate (N=17), CR occurred in 4 (24%), PR was 0, mCR was 5 (29%), stable disease was 2 (12%), progression was 0, not evaluable was 3 (18%), HI in 9 (53%). In high risk (N=23), CR occurred in 2 (9%), PR in 1 (4%), mCR was 8 (35%), stable disease was 6 (26%), progression was 1 (4%), not evaluable was 4 (17%), and HI in 7 (30%). In very high risk (N=33), CR occurred in 5 (15%), PR was 0, mCR was 10 (30%), stable disease was 2 (6%), progression was 4 (12%), not evaluable was 11 (33%), and HI in 11 (33%).

Safety-optimization strategies were employed to minimize genitourinary toxicities of hematuria and dysuria.

Conclusions: Oral rigosertib with azacitidine demonstrated efficacy in HMA-naive patients. The combination markedly improved hematopoiesis and reduced blasts in those HMA-failure MDS patients. The combination was well-tolerated in repetitive cycles for 25+ months. Risk mitigation strategies reduced urinary AEs in the expansion cohort. A pivotal Phase 3 trial is planned in an HMA-naive patient population.

TREATMENT OF HIGHER-RISK MDS

- Azacitidine is standard of care for HR-MDS patients
- Clinical responses in MDS 38-50%²
 - CR rate 7-24%
 - Recent studies failed to demonstrate improved clinical benefit with combination therapies compared to single agent AZA
 - (Ades L, et al., #467, ASH 2018)² (Sekeres M, et al., Intergroup JCO 2017)¹

ADVERSE EVENTS

Treatment Emergent Adverse Events (\geq 30%) in MDS Patients (N = 74)

	Number (%) of Patients				
MedDRA Preferred Term	All grades	Grade 1	Grade 2	Grade ≥3	
Any Event	74 (100)	74 (100)	70 (95)	65 (88)	
Hematuria	33 (45)	12 (16)	14 (19)	7 (9)	
Constipation	32 (43)	19 (26)	13 (18)	-	
Diarrhea	31 (42)	22 (30)	5 (7)	4 (5)	
Fatigue	31 (42)	6 (8)	22 (30)	3 (4)	
Dysuria	28 (38)	15 (20)	6 (8)	7 (9)	
Pyrexia	27 (36)	22 (30)	4 (5)	1(1)	
Nausea	26 (35)	21 (28)	5 (7)	-	
Neutropenia	23 (31)	2 (3)	1(1)	20 (27)	

RESPONSE PER IWG 2006 AMONG MDS IPSS-R SUBGROUPS⁶

Response per IWG 2006	Low/Intermediate N=17	High N=23	Very high N=33	Unknown N=1
Complete remission	4 (24)	2 (9)	5 (15)	0
Partial remission	0	1 (4)	0	0
Marrow CR	5 (29)	8 (35)	10 (30)	0
Stable disease	2 (12)	6 (26)	2 (6)	0
Progression	0	1 (4)	4 (12)	0
Not evaluable	3 (18)	4 (17)	11 (33)	1 (100)
Hematologic improvement	9 (53)	7 (30)	11 (33)	0
Erythroid response	2 (12)	3 (13)	11 (33)	0
Platelet response	6 (35)	6 (26)	10 (30)	0
Neutrophil response	4 (24)	3 (13)	6 (18)	0

- All patients ultimately relapse or fail to respond; these patients have a poor prognosis, with a median overall survival (OS) of only 4-6 months⁴
- Novel better tolerated combination strategies for patients with MDS are required to improve the clinical outcome

Week 1

Oral

Rigosertib

only

Week 3 Oral Rigosertib

Week 4

No Treatment

Week 2 **Oral Rigosertib**

Azacitidine

(SC or IV)

COMBINATION DOSE ADMINISTRATION⁴

ORAL RIGOSERTIB 840 MG OR 1120 MG IN DIVIDED DOSES

Week 1: Oral rigosertib twice daily* Week 2: Oral rigosertib twice daily* + azacitidine (75 mg/m²/day SC or IV) Week 3: Oral rigosertib twice daily* Week 4: No treatment

*early AM/mid-afternoon PM


PATIENT CHARACTERISTICS – HR-MDS \geq 840 MG/DAY

HMA NAIVE & HMA FAILURE

Number of patients treate	ed	74
Age	Median	69
	Range	42-90
Sex	Male	44 (59%)
	Female	30 (41%)
IPSS classification	Intermediate-1	24 (32%)
	Intermediate-2	26 (35%)
	High	21 (28%)
	Unknown	3 (4%)
IPSS-R classification	Low	3 (4%)
	Intermediate	14 (19%)
	High	23 (31%)
	Very high	33 (45%)
	Unknown	1 (1%)
Prior HMA therapy	Azacitidine	26 (35%)
	Decitabine	6 (8%)
	Both	3 (4%)

Thrombocytopenia	22 (30)	-	3 (4)	19 (26)

PATIENTS WITH HR-MDS EVALUABLE FOR RESPONSE PER RIGOSERTIB TREATMENT GROUP HMA NAIVE & HMA FAILURE




Rationale for Expansion Cohort at a dose of 1120mg/day:

- Rigosertib as a single agent administered orally at dose of 1120 mg/day yielded the highest response rate of transfusion independence (44%) in lower risk MDS (Raza A, et al., #1689 ASH 2017)
- Pursue Safety Optimization Strategies in additional patients at a higher daily dose

DEFINITION OF EVALUABILITY

- In order for patients to be considered evaluable for response assessment
 - Patients must have been treated with doublet for at least 12 weeks unless

DURATION OF THE OVERALL RESPONSE



CONCLUSIONS

- Oral rigosertib in combination with AZA demonstrated efficacy in both HMA-naive and HMA-refractory MDS patients
- In HMA-naive MDS patients oral rigosertib at doses \geq 840 mg/day administered with AZA is associated with an ORR of 90% and a CR rate

The authors gratefully appreciate the contributions of clinical investigators, study personnel, and, above all, the patients who participated in the trial.



- Investigator has determined that patient has progressed during the first 12 weeks of treatment
- Investigator has determined that patient has responded within the first weeks of treatment but terminated treatment before 12 weeks

of 34%

• Oral rigosertib in combination with AZA was well tolerated and administered in repetitive cycles for more than two years

Safety optimization strategies mitigated urinary AEs in the expansion cohort

Based on the safety and efficacy profile of the combination in MDS, a pivotal Phase III trial is planned in an HMA naive population

REFERENCES/ACKNOWLEDGEMENTS

¹Sekeres MA, Othus M, List AF, et al. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.

²Ades, L., Guerci, A., Laribi, K., Peterlin, P., Vey, N., Thepot, S., Wickenhauser, S., Zerazhi, H., Stamatoullas, A., Wattel, E., Recher, C., Toma, A., Bouabdallah, K., Braun, T., Beyne-Rauzy, O., Gruson, B., Cheze, S., Park, S., Cluzeau, T., Nimubona, S., Bordessoule, D., Benramdane, R., Quesnel, B., Ame, S., De Botton, S., Chermat, F., Lejeune, J., Chevret, S., & Fenaux, P. (2018). A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial. Blood, 132(Suppl 1), 467. Accessed April 10, 2019. https://doi.org/10.1182/blood-2018-99-111756.

³Raza, A., Yalçın, C., Cimist, M., Shelton, R., Bilgrami, S. F., Heaney, M. L., & Ali, A. M. (2017). Long Term Responses to Rigosertib in Lower-Risk Myelodysplastic Syndromes (MDS) Patients. Blood, 130(Suppl 1), 5316. Accessed April 10, 2019. Retrieved from http://www.bloodjournal.org/content/130/Suppl 1/5316.

⁴Navada, S. C., Garcia-Manero, G., Atallah, E. L., Rajeh, M. N., Shammo, J. M., Griffiths, E. A., Khaled, S. K., Dakhil, S. R., Young, D. E., Odchimar-Reissig, R., Pemmaraju, N., Alvarado, Y., Ohanian, M. N., John, R. B., Zbyszewski, P. S., Maniar, M., Petrone, M. E., Fruchtman, S. M., & Silverman, L. R. (2018). Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients. Blood, 132(Suppl 1), 230.

⁵Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002). The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100(7), 2292-2302.

⁶Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., Pinto, A., Beran, M., de Witte, T. M., Stone, R. M., Mittelman, M., Sanz, G. F., Gore, S. D., Schiffer, C. A., & Kantarjian, H. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. *Blood*, 108(2), 419-425.